Outcomes and the role of adjuvant therapy of limited stage small cell lung cancer undergoing surgical treatment
10.3760/cma.j.cn112152-20190626-00397
- VernacularTitle:局限期小细胞肺癌手术治疗的疗效分析及辅助治疗模式
- Author:
Jing YU
1
;
Wen OUYANG
;
Zhao HUANG
;
Gang CHEN
;
Yan ZHOU
;
Yanling MAO
;
Junhong ZHANG
;
Conghua XIE
Author Information
1. 武汉大学中南医院放化疗科 湖北省肿瘤生物学行为重点实验室 湖北省临床癌症中心 430071
- Keywords:
Neoplasms, small cell lung;
Postoperative adjuvant therapy;
Prognosis
- From:
Chinese Journal of Oncology
2020;42(4):336-339
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the outcomes of limited stage small cell lung cancer (L-SCLC) undergoing surgical therapy and to explore the value of adjuvant therapy for those patients.Methods:A retrospective analysis was initialed for the L-SCLC patients who underwent the surgical treatment in the Zhongnan Hospital of Wuhan University from January 2012 to December 2018. The median disease-free survival (DFS) and overall survival (OS) were calculated by Kaplan-Meier method. Cox regression was used to explore the prognostic factors.Results:A total of 44 patients were included in our study. The median DFS was 25 months, 1- and 2-year DFS rate were 70.2% and 51.9%, respectively. The median OS was 41 months, 1- and 2- year OS rate were 88.4% and 69.9%, respectively. Multivariate analysis showed male ( RR=6.56, P=0.03), T3-4 ( RR=6.23, P=0.01), pathological lymph node metastasis ( RR=6.52, P=0.03) and adjuvant radiotherapy ( RR=0.13, P=0.002) were associated with disease relapse significantly. Moreover, pathological lymph node metastasis ( RR=3.62, P=0.01) coupled with sufficient adjuvant chemotherapy (≥4 cycles) ( RR=0.12, P=0.01) were independent prognostic factors of OS. Conclusions:Surgical therapy may be an alternative primary treatment for L-SCLC. Additional adjuvant radiotherapy can reduce the risk of recurrence. Giving sufficient course of adjuvant chemotherapy can improve OS.
